21st Century Program

JMS ( Jichi Medical School)
21 st Century
COE ( Center of Excellence)
Program
AAV and Its Application to Gene Therapy & Regenerative Medicine
Friday, September 30, 2005 (13:00 ~ 18:10)
Information and In-service Training Center
Opening Remark
Fumimaro Takaku
President of Jichi Medical School
Introduction
Keiya Ozawa
Program Leader, JMS 21st Century COE Program
AAV and Gene Therapy
Hiroaki Mizukami
Division of Genetic Therapeutics, Jichi Medical School
Jun Mimuro and Yoichi Sakata
Division of Cell and Molecular Medicine, Jichi Medical School
Yukihiko Hirai and Takashi Shimada
Nippon Medical School
Yuko Miyagoe-Suzuki and Shin-ichi Takeda
National Center of Neurology and Psychiatry
Takashi Okada
Division of Genetic Therapeutics, Jichi Medical School
Shin-ichi Muramatsu
Division of Neurology, Jichi Medical School
Glenn Pierce
Avigen, Inc., USA
AAV and Regenerative Medicine
Takeshi Endo
Chiba University
Takamasa Takeuchi and Tadahito Kanda
National Institute of Infectious Diseases
Masashi Urabe
Division of Genetic Therapeutics, Jichi Medical School
Secretariat
Division of Genetic Therapeutics
Center for Molecular Medicine, Jichi Medical School
Tel: 0285-58-7402 Fax: 0285-44-8675 E-mail: dgtcmm@jichi.ac.jp
http://www.jichi.ac.jp/idenshi/index.html
Photographed by Prof. Mark A. Kay in Nikko on July 27, 2005
R. Michael Linden
Mount Sinai School of Medicine, USA
David W. Russell
University of Washington, USA
Closing Remark
Shin-ichi Tominaga
Vice-Dean of Jichi Medical School
Cosponsored by
JMS 21st Century COE Program
Center for Molecular Medicine, Jichi Medical School

JMS
COE
JMS (Jichi Medical School) 21 st Century COE (Center of Excellence) Program
The 2ndNikko International Symposium 2005
AAV and Its Application to Gene Therapy & Regenerative Medicine
Date: Friday September 30, 2005
Venue: JMS Information and In-service Training Center
~~~~~~~~~~~~~ Symposium Program ~~~~~~~~~~~~~
Opening Remark
13:00 – 13:05
Fumimaro Takaku, M.D., Ph.D.
President of Jichi Medical School, Tochigi, Japan
Introduction
13:05 – 13:15
Keiya Ozawa, M.D., Ph.D.
Program Leader, JMS 21 st Century COE Program
AAV and Gene Therapy
Chairperson: Yoichi Sakata
13:15 – 13:35
Serotypes of AAV and tissue specificity in vivo
Hiroaki Mizukami, M.D., Ph.D.
Division of Genetic Therapeutics, Center for Molecular Medicine
Jichi Medical School, Tochigi, Japan
13:35 – 13:55
Phenotype correction of hemophilia A mice with adeno-associated virus vectors carrying
the B domain-deleted factor VIII gene
Jun Mimuro, M.D., Ph.D. and Yoichi Sakata, M.D., Ph.D.
Division of Cell and Molecular Medicine, Center for Molecular Medicine
Jichi Medical School, Tochigi, Japan
Chairperson: Shun Ishibashi
13:55 – 14:15
AAV-mediated gene therapy for lysosomal storage diseases
Yukihiko Hirai, Ph.D. and Takashi Shimada, M.D., Ph.D.
Department of Biochemistry and Molecular Biology
Division of Gene Therapy, Research Center for Advanced Medical Technology
Nippon Medical School, Tokyo, Japan
14:15 – 14:35
Recombinant adeno-associated virus (rAAV) as a therapeutic tool for Duchenne muscular
dystrophy (DMD)
Yuko Miyagoe-Suzuki, M.D., Ph.D. and Shin-ichi Takeda, M.D., Ph.D.
Department of molecular Therapy, National Institute of Neuroscience
National Center of Neurology and Psychiatry, Tokyo, Japan
Chairperson: Toshihiko Yada
14:35 – 14:55
Gene therapy for lifestyle-related diseases
Takashi Okada, M.D., Ph.D.
Division of Genetic Therapeutics, Center for Molecular Medicine
Jichi Medical School, Tochigi, Japan
14:55 – 15:15
Gene therapy for Parkinson's disease: strategies for clinical applications
Shin-ichi Muramatsu, M.D., Ph.D.
Divisions of Neurology and Oriental Medicine
Jichi Medical School, Tochigi, Japan

Chairperson: Imaharu Nakano
15:15 – 15:45
Host immunity to AAV vectors: impact on gene therapy
Glenn Pierce, Ph.D., M.D.
Consultant, Gene Therapy Clinical Development
Formerly Vice President, Research and Clinical Development, Avigen, Inc., Alameda, U.S.A.
15:45 – 16:00
AAV and Regenerative Medicine
Chairperson: Eiji Kobayashi
16:00 – 16:20
Muscle dedifferentiation and regeneration induced by AAV vector-mediated gene transfer
Takeshi Endo, Ph.D.
Department of Biology, Faculty of Science
Chiba University, Chiba, Japan
Chairperson: Hiroaki Okamoto
16:20 – 16:40
Characterization of an insulator in AAVS1
Takamasa Takeuchi, Ph.D., M.D. and Tadahito Kanda, Ph.D.
Division of Molecular Genetics
National Institute of Infectious Diseases, Tokyo, Japan
16:40 – 17:00
Site-specific integration of a therapeutic gene into mesenchymal stem cells
Masashi Urabe, M.D., Ph.D.
Division of Genetic Therapeutics, Center for Molecular Medicine
Jichi Medical School, Tochigi, Japan
Chairperson: Yutaka Hanazono
17:00 – 17:30
Targeted gene delivery to embryonic stem cells
R. Michael Linden, Ph.D.
Department of Gene and Cell Medicine
Department of Microbiology
Mount Sinai School of Medicine, New York, U.S.A.
Chairperson: Keiya Ozawa
17:30 – 18:00
Targeted and random integration of AAV vectors
David W. Russell, M.D., Ph.D.
Department of Medicine
University of Washington, Seattle, U.S.A.
Closing Remark
18:00 – 18:10
Shin-ichi Tominaga, M.D., Ph.D.
Vice-Dean of Jichi Medical School, Tochigi, Japan
18:15 ~19:30 Buffet-style dinner party at the SEIYODO restaurant
Secretariat
Division of Genetic Therapeutics, Center for Molecular Medicine, Jichi Medical School
3311-1 Yakushiji, Minamikawachi-machi, Kawachi-gun, Tochigi 329-0498, Japan
TEL: +81-285-58-7402 FAX: +81-285-44-8675 E-mail: dgtcmm@jichi.ac.jp